Alzheimer's disease (AD) is the leading cause of dementia and remains without a disease-modifying cure, in part because most approved therapies target symptoms rather than the underlying molecular drivers of neurodegeneration. Dual-specificity tyrosine phosphorylation-regulated kinase 1A (DYRK1A) has emerged as a mechanistically attractive target because it phosphorylates tau at pathological residues and modulates amyloid precursor protein processing, placing it upstream of both hallmark AD pathologies. This study combined sequence-level bioinformatics with structure-based drug design to evaluate the human DYRK1A kinase domain (PDB ID: 7O7K) as a template for inhibitor discovery. BLASTP and phylogenetic analysis confirmed the identity and evolutionary conservation of the retrieved sequence, while ERRAT (quality factor 96.37%) and Ramachandran plot analysis (88.7% of residues in the most favoured region, no residues in disallowed regions) established that the structure was of sufficient stereochemical quality for downstream docking. Protein-protein interaction mapping using STRING placed DYRK1A within a ten-partner interaction hub linked to DNA-damage repair, calcineurin-NFAT signalling, and transcriptional regulation, and cross-referencing this network against the KEGG Alzheimer's disease pathway (hsa05010) supported its disease relevance. Blind docking of five candidate ligands, pazopanib, kaempferol, emodin, sunitinib, and the co-crystallized reference inhibitor abemaciclib, against the validated receptor using CB-Dock and AutoDock Vina identified pazopanib as the strongest predicted binder of the DYRK1A ATP-binding cleft (Vina score −10.3 kcal/mol, cavity volume 5685 ų), with abemaciclib a close second (−10.7 kcal/mol at a smaller cavity) and the remaining three ligands showing consistent, overlapping engagement of the same pocket. These findings support DYRK1A as a structurally and biologically validated target and nominate pazopanib as a candidate for further ADMET profiling and molecular dynamics evaluation as part of a drug-repurposing strategy against Alzheimer's disease.